World Leaders in Biomarker and Bioanalysis Research Services

We are deeply saddened to share the news with you that our friend, colleague, mentor and Chief Scientific Officer, Matti Kimberg, unexpectedly passed away on 10 July 2022. Matti was not only a truly extraordinary scientist but more importantly also a remarkable person whose gentle nature, enthusiasm and sincere concern for people left an indelible mark on all that he met. Matti was instrumental in helping to weave the fabric of Synexa’s ethos and identity and he will be greatly missed.

Our hearts go out to Matti’s family and loved ones for whom this is as much a shock as it is to his Synexa Family. Your patience and support will be greatly appreciated over this period. Dr. Justin Devine (Synexa’s CMO) will in the interim take on the role of Chief Scientific Officer.

In memory of Matti Kimberg

Biomarker & Bioanalytical expertise

Synexa Life Sciences has been providing expert insights for the clinical development of therapeutics for almost 20 years.

Insights that will improve the quality of decision-making through each stage of a therapeutic’s development.

Invaluable insight into the bioanalytical profile of large molecule therapeutics.

In vitro solutions

Our human in vitro translational ProtoTrials® platform provides unique and translatable insights into a therapeutic’s potential, safety and efficacy.

Services &
Capabilities

Synexa Life Sciences has been providing expert insights for the clinical development of therapeutics for almost 20 years.
services
capabilities
Synexa specializes across a wide range of therapeutic areas with special focus in immunology, immuno-oncology, autoimmunity among other areas.

Bridging the gap between science and life.

Discuss real solutions to develop your therapeutic pipeline.

Join our next live webinar

Join us as we discuss overcoming challenges to COVID-19 clinical trials, on Tues 27 Jul 2021.

News and
articles